Simple, Fast Aldosterone and Renin Measurement
Our Immunodiagnostic Systems Limited (referred to hereafter as IDS) hypertension panel currently offers two fully-automated, non-radioactive immunoassays for the measurement of Aldosterone and Direct Renin from the same plasma sample to improve laboratory workflow.
30% of the adult population suffer from hypertension and out of these, 15-20% of hypertensive patients may have Primary Aldosteronism (PA) or Renovascular Hypertension (RVH).1,2,3 In PA excess, aldosterone levels may be produced due to an adenoma (Conn’s syndrome) or hyperplasia, causing blood pressure elevation.4 Patients with this condition are at a stronger risk of heart disease and stroke than those with essential hypertension.4 PA patients also have higher cardiovascular morbidity and mortality than age and sex-matched patients with essential hypertension. RVH is due to the narrowing of one or both of the renal arteries as a result of an atherosclerotic plaque or fibro muscular dysplasia.
According to the Endocrine Society guidelines, both Renin and Aldosterone need to be measured as the Aldosterone to Renin ratio (ARR) is the screening test for PA.5 An elevated ARR is indicative of the presence of PA. The measurement of Renin can also be used to stratify risk of essential hypertension patients. The fully-automated IDS hypertension panel provides laboratories with simple and fast quantitative determination of Renin and Aldosterone.
1. Kearney, PM et al., Global burden of Hypertension: analysis of worldwide data. Lancet, 2005.
2. Rossi, GP et al., Clinical use of laboratory test for the identification of secondary hypertension, Crit Rev Clin Lab Sci, 2007.
3. Mulatero, P et al., Increased diagnosis of Primary aldosteronism in centers from five continents. JCEM, 2004.
4. Milliez, P. et al., Evidence for an increased rate of cardiovascular events in patients with primary Aldosteronism. J Am Coll Cardiol 2005 Apr 19; 45 (8): 1243-8.
5. Funder, J.W. et al., Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93 (9) 3266-81.